Date: 2012-01-04
Type of information: Fundraising
Company: Pharmalink (Sweden)
Investors: existing shareholders
Amount: SEK 35 million (€4million)
Funding type:
Planned used: The new funds will be used to further advance Nefecon® and Busulipo™, Pharmalink's two lead product candidates. Nefecon® is the first pharmaceutical product especially developed for patients with IgA nephropathy, the most common form of primary glomerulonephritis and a cause of end-stage renal disease requiring treatment with dialysis or transplantation. Nefecon® has shown positive results in an open-labeled Phase II trial evaluating safety and efficacy and Pharmalink is currently focusing on preparing pivotal clinical trials. Busulipo® (busulfan) is being developed to provide a best-in-class conditioning agent for use priorto hematopoietic stem cell transplantation (HSCT). The product has successfully undergone Phase II clinical trials and extensive data on efficacy, safety and pharmacokinetics compare positively with historical controls. Pharmalink is currently preparing for late stage clinical trials and for the registration and introduction of Busulipo® into key global markets.
Others: Pharmalink has raised SEK 35 million through a rights issue of new shares to the Company's existing shareholders, including Industrifonden.
Therapeutic area: Renal diseases
